Breaking News

Savient Appoints Co-Presidents

June 21, 2013

Crowley, Hamill, and Yachmetz take over for Ferrari

Savient Pharmaceuticals, Inc. has appointed Richard Crowley as co-president and chief operating officer, John P. Hamill, who will serve as co-president and chief financial officer, and Philip K. Yachmetz, who will serve as co-president and chief business officer. Louis Ferrari, president, chief executive officer, and director, is leaving the company to pursue other interests.
 
The board of directors thanks Mr. Ferrari for his valuable contributions throughout his tenure and wishes him well in his future endeavors.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments